GlaxoSmithKline Pakistan Limited, a biopharma company, engages in the discovery, development, and delivery of medicines and vaccines in Pakistan. It offers products in the anti-infective, dermatology, respiratory, immunology and inflammation, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, Shingrix, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakista... [
GLAXO — GlaxoSmithKline Pakistan Limited
Sector: Pharmaceuticals · Pakistan Stock Exchange
⚠ Prices: 6 Nov 2026 — PSX end-of-day close (feed fetched 23:14 PKT) · Fundamentals: public data collected 6 Nov 2026 · Not live prices.Summary — GLAXO
| Measure | Value |
|---|---|
| Price (Rs, 6 Nov — PSX delayed feed) | 337.31 |
| Change, 6 Nov session (delayed) | -0.79% |
| Volume (shares, 6 Nov session) | 183,864 |
| Market capitalisation | Rs 107.42 bn |
| Revenue (TTM) | Rs 69.53 bn |
| Price / Earnings (P/E) | 9.70 |
| Price / Book (P/B) | 2.94 |
| Dividend yield | 5.40% |
| Return on equity (ROE) | 32.40% |
| Net margin | 15.20% |
| Debt / Equity (as reported by source) | 1.10% |
| Revenue growth, 3-year | 16.30% |
Company Snapshot
| Paid-up Capital | Rs 3,184.67 mn |
| Authorized Capital | Rs 5,000.00 mn |
| Shares Outstanding | 318.47 mn |
| Free Float | 63.69 mn |
| Free Float % | 20.00 % |
| Face Value | Rs 10.00 |
| Fiscal Year End | December |
| Avg Volume (12M) | 261,377 |
| Book Value / Share | Rs. 108.12 (Upto 2026 2Q) |
| Total Book Value (computed) | Rs 34.43 bn |
Capital data: SCSTRADE company snapshot, collected 6 Nov 2026. Total Book Value is computed on this page as Book Value / Share × Shares Outstanding.
PSX Scorecard — five checks on this stock's own data
VALUE
4/6
FUTURENo forecast data
PAST
6/6
HEALTH
6/6
DIVIDEND
5/6
Strongest: Past performance (6/6). Weakest: Value (4/6).
How this is scored
Scores are computed mechanically from the data on this page, 0–6 per axis, scaled over the checks that could be run — an axis with no data is labelled, never scored zero for missing data. VALUE: upside to the average analyst target (bands from +30% down), P/E and P/B below the sector median, yield above the sector median. FUTURE: S&P consensus forward EPS and revenue growth bands (only where estimates exist). PAST: revenue and EPS growth across the published financial history, latest year profitable, ROE bands. HEALTH: debt/equity bands, positive latest net margin, no loss-making year in the history. DIVIDEND: yield bands, years of recorded DPS, DPS trend, and payout (DPS ÷ EPS) at or under 100%. The full rule table is in the site's data inventory. Scores are a data summary, not a recommendation.
Performance — GLAXO
1W+4.3%
1M+10.5%
3M-3.7%
6M-3.3%
1Y-12.5%
Returns computed from daily closes to 05 Nov 2026 (Yahoo Finance PSX series, collected 6 Nov 2026); each bar is scaled to the largest move shown.
52-week range — daily-close series
52-week lowRs 293.09Now Rs 337.31
+15.1% above low · −25.1% below high52-week highRs 450.61
+15.1% above low · −25.1% below high52-week highRs 450.61
Day range — 6 Nov 2026 session
Day lowRs 333.00Close Rs 337.31Day highRs 340.90
Day high/low from the official PSX market-summary feed for the 6 Nov 2026 session.
Investment Case — GLAXO
Strengths — from the numbers
- Revenue grew +79.8% across the published history, FY2021–FY2025 (Rs 36,661m → Rs 65,901m).
- Earnings per share grew +87.3% across the published history, FY2021–FY2025 (Rs 16.81 → Rs 31.48).
- Net margin improved to 15.21% in FY2025, from 14.61% in FY2021.
- Return on equity of 32.40% on the dataset's trailing figures.
- Debt/equity of 0.01 — below 1 (the source reports this figure as 1.10%).
- Dividends recorded in every one of the 3 years in the published record; latest DPS Rs 17.00 (2025), a dividend yield of 5.40% at the current price.
Risks / watch points — from the numbers
- No dividend was recorded for 2022 in the source's dividend history.
- No dividend was recorded for 2023 in the source's dividend history.
- Share price is down -12.5% over the past year on the chart series (2025-11-06 → 2026-11-05).
Recent performance — FY2025
| Revenue | Rs 65,901m (+7.7% vs FY2024) |
| Net income | Rs 10,025m (+53.4% vs FY2024) |
| EPS | Rs 31.48 (+53.4% vs FY2024) |
| Net margin | 15.21% |
Latest published fiscal year from the financial history below (StockAnalysis figures, collected 6 Nov 2026).
Generated from the figures above — PSX Analysis data summary, not investment advice.
Upcoming Result — Broker Forecasts
Expected Dividend — Broker Estimate
| House | Expected dividend / share | Expected yield |
|---|---|---|
| SCSTRADE (Standard Capital Securities) | Rs 16.26 | 4.82% |
House's published expected dividend, Upto 2026 3Q — SCSTRADE company snapshot, collected 7 Nov 2026.
Forecasts are the publishing houses' own estimates — not actual results and not PSX Analysis estimates.
Quotes — GLAXO
| Quote | Value |
|---|---|
| Last price (Rs) | 337.31 |
| Change, 6 Nov session | -0.79% |
| Day open, 6 Nov (Rs) | 340.00 |
| Day high, 6 Nov (Rs) | 340.90 |
| Day low, 6 Nov (Rs) | 333.00 |
| Previous close — LDCP (Rs) | 340.01 |
| Volume (shares, 6 Nov session) | 183,864 |
| Market capitalisation | Rs 107.42 bn |
| 1-year high (chart series, Rs) | 450.61 |
| 1-year low (chart series, Rs) | 293.09 |
| 1-year change (chart series) | -12.5% |
Day open/high/low and previous close (LDCP) are from the official PSX market-summary feed for the 6 Nov 2026 session, the same feed that supplies the closing price. 1-year figures are computed from the daily-close chart series below.
Last 10 trading sessions
| Date | Close (Rs) | Change |
|---|---|---|
| 05 Nov 2026 | 340.01 | +3.19% |
| 04 Nov 2026 | 329.51 | +3.73% |
| 03 Nov 2026 | 317.65 | -0.10% |
| 02 Nov 2026 | 317.97 | -0.44% |
| 30 Oct 2026 | 319.39 | -2.03% |
| 29 Oct 2026 | 326.01 | +3.50% |
| 28 Oct 2026 | 315.00 | +0.06% |
| 27 Oct 2026 | 314.82 | +2.44% |
| 26 Oct 2026 | 307.31 | -0.62% |
| 23 Oct 2026 | 309.23 | -0.32% |
Daily closes: Yahoo Finance PSX series, collected 6 Nov 2026. The series records closes only, so no volume column is shown.
Technical Chart — GLAXO
Loading chart…
Daily candles — Yahoo Finance daily data to 6 Nov 2026 · End-of-day, delayed — not real-time prices.
2024-11-06 → 2026-11-06 · +20.4% over the period · 514 trading days · Moving averages, RSI and MACD are computed in your browser from the same daily bars. Trend lines connect the two most recent swing highs/lows.
1-year returns compared
| 1-year price change | Change |
|---|---|
| GLAXO (this stock) | -12.5% |
| Sector median — Pharmaceuticals (median of 12 stocks in our dataset) | -13.0% |
| All listed stocks median (median of 440 stocks in our dataset) | -6.2% |
Price change only (dividends not included), from the daily-close series above.
Technicals — GLAXO
Moving averages
| Average | Value (Rs) | Price vs average |
|---|---|---|
| MA20 — 20-session average | 316.31 | Price Above |
| MA50 — 50-session average | 316.66 | Price Above |
| MA200 — 200-session average | 347.57 | Price Below |
RSI (14) — 70.6 · Overbought
030 — oversold below70 — overbought above100
Wilder RSI(14) computed from the daily-close series. RSI is a momentum gauge, not a buy or sell signal.
Classic pivot levels — from the 6 Nov session
| Level | Rs |
|---|---|
| Resistance 2 (R2) | 344.97 |
| Resistance 1 (R1) | 341.14 |
| Pivot point (PP) | 337.07 |
| Support 1 (S1) | 333.24 |
| Support 2 (S2) | 329.17 |
Classic pivots from the 6 Nov 2026 session's high (Rs 340.90), low (Rs 333.00) and close (Rs 337.31) in the official PSX feed. The close sits above the pivot point.
Signals summary
| Reading | Status |
|---|---|
| Price vs MA20 | Above |
| Price vs MA50 | Above |
| Price vs MA200 | Below |
| RSI (14) zone | Overbought (70.6) |
| MACD vs signal line | Above |
| Short-term trend (MA20 vs MA50) | Down |
| Medium-term trend (MA50 vs MA200) | Down |
| Long-term trend (price vs MA200) | Down |
Trend labels compare the named averages (long-term compares the price with MA200); “Up” means the first-named sits above the second. Mechanical readings from daily closes — not investment advice.
Technicals are mechanical calculations on past prices. Based on daily closes to 05 Nov 2026. They describe momentum and recent trading ranges only — not investment advice.
Company — GLAXO
| Company | GlaxoSmithKline Pakistan Limited |
| Symbol | GLAXO |
| Sector | Pharmaceuticals |
| Market capitalisation | Rs 107.42 bn |
| Revenue (TTM) | Rs 69.53 bn |
Founded 2001 · Employees 1,606 — as published by StockAnalysis.
Company description: StockAnalysis company profile, collected 6 Nov 2026.
Exchange record: PSX company profile for GLAXO (Pakistan Stock Exchange data portal).
Financials — GLAXO
Revenue (TTM)
Rs 69,525m
Rs 69,525m
Net income (TTM)
Rs 10,984m
Rs 10,984m
EPS (TTM)
Rs 34.49
Rs 34.49
Net margin (TTM)
15.80%
15.80%
P/E
9.70
9.70
P/B
2.94
2.94
Dividend yield
5.40%
5.40%
ROE
32.40%
32.40%
Net margin
15.20%
15.20%
Debt / Equity
1.10%
1.10%
| Measure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue (Rs m) | 36,661 | 41,842 | 49,661 | 61,188 | 65,901 |
| Operating income (Rs m) | 6,873 | 5,068 | 1,965 | 10,252 | 16,360 |
| Net income (Rs m) | 5,354 | 2,463 | 534 | 6,536 | 10,025 |
| EPS (Rs) | 16.81 | 7.73 | 1.68 | 20.52 | 31.48 |
| Net margin | 14.61% | 5.89% | 1.07% | 10.68% | 15.21% |
Trailing twelve months (to Sep 30, 2026, not a completed fiscal year): Revenue Rs 69,525m · Net income Rs 10,984m · EPS Rs 34.49 · Net margin 15.80%.
Source: StockAnalysis financials, collected 6 Nov 2026 — this stock's published history here spans FY2021–FY2025 (5 fiscal years; the source table publishes a maximum of five completed years per stock). A dash means the source did not publish that figure for that year.
Dividend History
| Dividend per share (Rs, per fiscal year) | 2021 | 2024 | 2025 |
|---|---|---|---|
| DPS | 7 | 10 | 17 |
A dash means no dividend was recorded for that year in the source. Source: StockAnalysis dividend history, collected 6 Nov 2026.
All recorded dividend payments
Payments recorded since 2022 — StockAnalysis, collected 7 Nov 2026.
| Ex-dividend date | Dividend (Rs) | Pay date |
|---|---|---|
| Sep 2, 2026 | 7.000 | Sep 11, 2026 |
| Apr 24, 2026 | 12.000 | May 6, 2026 |
| Sep 5, 2025 | 5.000 | Sep 19, 2025 |
| Apr 18, 2025 | 10.000 | May 7, 2025 |
| Apr 15, 2022 | 7.000 | May 9, 2022 |
Payout ratio, FY2025: dividend per share Rs 17.00 ÷ EPS Rs 31.48 = 54.0% of earnings paid out as dividends.
Valuation & Fair Value — GLAXO
Fair P/E Value — sector multiple
Rs 424.23
Current price Rs 337.31 · +25.8%
Formula: sector median P/E 12.30× × EPS Rs 34.49 = Rs 424.23. Sector median across 12 Pharmaceuticals peers with a published P/E — the same basis as the median table below. EPS is the trailing-twelve-month (TTM) figure published in the dataset.
Fair P/B Value — sector multiple
Rs 317.87
Current price Rs 337.31 · -5.8%
Formula: sector median P/B 2.94× × book value per share Rs 108.12 = Rs 317.87. Sector median across 11 Pharmaceuticals peers with a published P/B — the same basis as the median table below. Book value per share from the SCSTRADE company snapshot (Upto 2026 2Q), collected 6 Nov 2026.
1 of 2 measures above the current price. Each measure stands on its own stated basis — they are deliberately not blended into a single fair value. Mechanical estimates computed from published data; not investment advice.
| Measure | GLAXO | Sector median |
|---|---|---|
| Price / Earnings (P/E) | 9.70 | 12.30 |
| Price / Book (P/B) | 2.94 | 2.94 |
| Dividend yield | 5.40% | 1.50% |
| Return on equity (ROE) | 32.40% | 21.65% |
Sector median across 14 listed peers in our dataset (sector: Pharmaceuticals), computed only from peers where the measure is published; a median is shown only when at least 5 peers have the measure.
Calendar — GLAXO
| Ex-dividend date | Dividend (Rs) | Pay date | Status |
|---|---|---|---|
| Sep 2, 2026 | 7.000 | Sep 11, 2026 | Paid |
| Apr 24, 2026 | 12.000 | May 6, 2026 | Paid |
| Sep 5, 2025 | 5.000 | Sep 19, 2025 | Paid |
| Apr 18, 2025 | 10.000 | May 7, 2025 | Paid |
| Apr 15, 2022 | 7.000 | May 9, 2022 | Paid |
Dividend dates as recorded by StockAnalysis (collected 6 Nov 2026); past payments are labelled Paid. Market-closed days that affect settlement: PSX Holidays 2026 · more yields and payers on the dividend hub.
Sector — GLAXO
GLAXO ranks #1 by market capitalisation among the 14 listed Pharmaceuticals stocks in our dataset. Full sector tables: Sectors.
FAQ — GLAXO
What is the current GLAXO share price?
GlaxoSmithKline Pakistan Limited (GLAXO) last traded at Rs 337.31 in the 6 Nov 2026 session, -0.79% on the day. Prices on this page are the PSX end-of-day close from the official delayed feed, not live prices.
What is GLAXO's 52-week range?
Across the daily-close series (2025-11-06 to 2026-11-05), GLAXO traded between Rs 293.09 and Rs 450.61. The latest close in the series was Rs 340.01.
Which PSX sector is GLAXO in?
GlaxoSmithKline Pakistan Limited (GLAXO) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
What is the latest GLAXO dividend?
Total dividend per share for fiscal 2025 was Rs 17.00; the most recent recorded payment is Rs 7.00 per share (ex-date Sep 2, 2026, pay date Sep 11, 2026). Dividend history as recorded by StockAnalysis, collected 6 Nov 2026.
What are GLAXO's P/E ratio and dividend yield?
GlaxoSmithKline Pakistan Limited (GLAXO) shows a P/E ratio of 9.70 and a dividend yield of 5.40% in the public data collected 6 Nov 2026.
Answers are generated from this page's own figures (public data collected 6 Nov 2026; prices are the 6 Nov 2026 PSX end-of-day close, not live).
GlaxoSmithKline Pakistan Limited (GLAXO) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
Every figure above comes from public listings collected on 6 November 2026 (StockAnalysis and SmartMoney, merged by symbol), with the price, change and volume refreshed on 6 Nov 2026 from the official PSX delayed market feed (end-of-day close, fetched 23:14 PKT) — delayed figures, not live prices. If this stock was absent from that feed, its price is the previous latest close. A dash means the measure was not published for this stock by the sources, not that it is zero. Compare GLAXO with the market's largest shares in the Top 250 screener, browse the whole market in Stocks A–Z, and read the ratios explainer in Learn.
This page is a data summary for education, not a recommendation to buy or sell GLAXO.